ARKG - ARK Genomic Revolution ETF
|Ex-Dividend Date||Dec 29, 2020|
|Trading Day||April 21|
|Day's Range||84.69 - 88.23|
|52-Week Range||36.91 - 115.15|
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
|Asset Class |
|Inception Date |
Oct 31, 2014
|Ticker Symbol |
Top 10 Holdings44.72% of assets
|Pacific Biosciences of California||PACB||4.39%|
|NOVARTIS AG-SPONSORED ADR||NVSN.MX||4.09%|
|ROCHE HOLDINGS LTD-SPONS ADR||RHHBY||3.61%|
|Dec 29, 2020||$0.36456||Jan 1, 1970|
|Dec 27, 2019||$1.05395||Dec 31, 2019|
|Dec 27, 2018||$0.46634||Dec 31, 2018|
|Dec 27, 2017||$0.135||Dec 29, 2017|
|Dec 28, 2016||$0.00||Jan 4, 2017|
|Dec 24, 2015||$0.00||Dec 31, 2015|
The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is a prime example of an exchange traded fund with lots of levers to pull. Since it's an actively managed fund, it's worth examining some of the...
Cathie Wood says digital wallets and genomics are the next big sector boom
Ark Invest's Cathie Wood joins 'The News with Shepard Smith' to talk about why she's still bullish on Tesla and electric vehicles. She also believes digital wallets and genomics will be the next sectors...
Early cancer detection is an emerging frontier for healthcare companies. The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is among the exchange traded funds best positioned to capitalize on tha...
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is obviously positioned as a genomics fund, but as an actively managed exchange traded fund, it can venture into other growth areas in the healt...
Cathie Wood-led Ark Investment Management on Friday bought in more shares of the blank-check company Jaws Spitfire Acquisition Corp (NYSE: SPFR), its third such purchase for its newest fund Ark Space Ex...
Patients may suffer from the same ailments, but no two medical problems are exactly alike. That much is confirmed by genetic code, indicating the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is...
Alibaba, Amazon, Palantir, Google, Takeda, Unity — What Cathie Wood's Ark Bought And Sold On Thursday
Cathie Wood's Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain s...
Thematic ETFs saw net inflows of $42.6 billion in the first two months of this year, more than three times the $13.3 billion garnered in the same period last year.
The DNA sequencing and genomics markets move fast. Good news for investors: the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is up to speed.
ARK Invest buys this week have some stocks taking off as the private investment firm picks up shares on the stock market dip. The post ARK Invest Buys: What Stocks Is Cathie Wood Buying on the Dip This ...
There's a pretty good chance the answer is "yes."
Ark Invest funds like the ARKK ETF are falling today thanks to big bets on Tesla and Bitcoin. Here's why the big picture is still bright.
Reddit traders follow playbook from 'Queen' Cathie Wood
CNBC's Kate Rooney reports on the Reddit interest in Ark Invest's Cathie Wood and the growth of Ark Invest's funds.
The February rally has been historic, and investors seem optimistic amid signs of economic recovery, the vaccine rollout, and more positive news. Nonetheless, there are fears of a bubble.
Get the latest on the red-hot active ETF manager's moves.
When it comes to investing in companies with exposure to the rapidly evolving early cancer detection/screening market, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) stands above the rest. Pa...